Acceleron  

Clinical Trials

In collaboration with Celgene, the MEDALIST Phase III study has been developed to investigate how well an investigational medicine called luspatercept works on lower risk myelodysplastic syndromes patients. The main goal of the study is to see if luspatercept increases red blood cell counts so blood transfusions are not needed. Approximately 210 patients from the around the world will participate in this study. To learn more about this trial, please click here.

In collaboration with Celgene, the BELIEVE Phase III study has been developed to investigate how well an investigational medicine called luspatercept works on regularly transfused beta-thalassemia patients. The main goal of the study is to see if luspatercept increased red blood cell counts so blood transfusion burden is reduced. Approximately 300 patients from around the world will participate in this study. To learn more about this trial, please click here.

The DART Phase II study has been developed to investigate how well an investigational medicine called dalantercept, in combination with axitinib works in patients with renal cell carcinoma. The main goal of the study is to see if dalantercept in combination with axitinib prolongs progression free survival compared to axitinib alone. Approximately 130 patients from around the United States will pariticipate in this study. To learn more about this trial, please click here.

Visit www.clinicaltrials.gov for more information on all of Acceleron’s clinical trials.


Drug Study Phase Disease Study ID
Luspatercept MEDALIST – Phase III Study Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) NCT02631070
Luspatercept BELIEVE – Phase III Study Beta-thalassemia NCT02604433
Luspatercept Phase II Extension Study MDS NCT02268383
Luspatercept Phase II Extension Study Beta-thalassemia NCT02268409
Luspatercept Phase II Beta-thalassemia NCT01749540
Luspatercept Phase II Anemia in Low or Intermediate-1 Risk Myelodysplastic Syndromes NCT01749514
Sotatercept Phase IIa Anemia in Chronic kidney disease (CKD) / End-stage Renal Disease (ESRD) NCT01999582
Dalantercept Phase II Advanced Renal Cell Carcinoma (RCC) NCT01727336
ACE-083 Phase II Facioscapulohumeral Muscular Dystrophy (FSHD) NCT02927080

Acceleron trials listed as recruiting or active on www.clinicaltrials.gov